switzerlanden
US-China conflict: the pressure intensifies on ADRs

US-China conflict: the pressure intensifies on ADRs

27-05-2020 | Insight
Over the past few weeks, the US has ratcheted up its rivalry with China, with various announcements that go beyond a focus on restricting trade of goods. In early May, US administration officials announced a policy to restrict the Federal Retirement Thrift Investment Board from investing in Chinese equities. This was followed by further restrictions on Huawei’s access to products based on US technology. Now, in the latest shot across the bows, the Senate has overwhelmingly approved a bill that could lead to Chinese companies being barred from listing on US stock exchanges.
  • Jan de Bruijn
    Jan
    de Bruijn
    Client Portfolio Manager
  • Jaap  van der Hart
    Jaap
    van der Hart
    Equity Fund Manager

Speed read

  • Upcoming US legislation likely to hurt Chinese ADRs listed in the US
  • In response, US-listed Chinese companies may move to Hong Kong
  • These developments do not affect our stance on China, for now

On 20 May, the Senate unanimously passed the ‘Holding Foreign Companies Accountable’ (HFCA) Act. The bill aims to prohibit a company from being listed on any of the US securities exchanges if that company has failed to comply with the Public Company Accounting Oversight Board’s (PCAOB) audits for three years in a row.

The bill also requires all public companies to disclose whether they are owned by a foreign state. There is a three-year grace period on these requirements. The bill now needs to pass the House before reaching the President’s desk to be signed into law. Although the bill covers all listed companies, in practice it will mainly have an impact on Chinese US-listings.

China is the only large country that refuses to allow the PCAOB to inspect audits of companies registered in China and Hong Kong, arguing that Chinese law bars the work of auditors from being transferred out of the country. We expect the House to approve the bill and the President of the US (Republican or Democrat) to sign it, as there is rare but strong bipartisan support for the bill.

China is unlikely to accept the US demand for full PCAOB access as it will consider this a sovereignty issue. Furthermore, the demand by the Senate bill for a full disclosure of state ownership and party membership of senior managers of the ADRs makes any concession by the Chinese government even harder politically.

There are currently 233 Chinese ADRs listed in the US (primary listings only), with an aggregate listed market capitalization of USD 1.03 trillion, representing 3.3% of the total US equity market capitalization and 8% of China’s total market capitalization. On average, these ADRs collectively trade USD 8.1 billion per day, which represents 6% of the average daily turnover in the US. In other words, Chinese ADRs trade twice as much as US stocks.

It has been estimated by Goldman Sachs that US investors currently hold USD 350 billion worth of Chinese ADRs, representing roughly one third of the ADR universe. Goldman Sachs further estimates that 29 of the 233 ADRs, with a total market capitalization of USD 370 billion, are eligible for a second listing in Hong Kong. We would expect many will now opt for a Hong Kong listing.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates
Subscribe

Positioning in EM strategies

Beyond the fact that the rising US-China tensions could negatively influence investor sentiment towards Chinese stocks, the implementation of the HFCA Act could also have a negative impact on our Chinese US-listed holdings. Table 1 highlights our exposure to China, including Chinese US-listed holdings. Our US-listed names will be affected by the new ADR rule to varying degrees, depending on the final details of the law and its implementation.

It is likely that the US-listed Chinese companies will move to another exchange

However, as already mentioned, it is likely that the US-listed Chinese companies will move to another exchange. The most likely option would be Hong Kong, though other exchanges, such as London, will also be considered.

Since Alibaba’s successful secondary listing in Hong Kong in 2019, it has been widely expected that other companies would follow suit. JD.com Inc. and NetEase Inc. have both filed for a secondary listing since then. Chinese search engine Baidu is also considering delisting from the US Nasdaq market and moving to an exchange closer to home. Thus, any negative impact on our strategies is expected to be limited in the longer term.

Investment implications

For now, we intend to maintain our current exposure to China. As Table 1 illustrates, Robeco Emerging Stars has a relatively small underweight position in China, while Robeco Emerging Markets Equities has a slight overweight. The Chinese ADRs held in the strategies are performing very well currently. Our base case scenario is for a mild to negative impact for these ADRs, with the potential for companies to move to Hong Kong’s stock exchange.

Table 1: Exposure of Robeco’s emerging strategies to Chinese equities

Source: Robeco, 26 May 2020.

However, the latest restrictions on US investments in China is a risk factor for the whole Chinese stock market, not just for the ADRs. The US developments notwithstanding, we continue to see other factors as positive for China, such as better control of the coronavirus pandemic, government economic stimulus and positive expected growth in 2020. The HFCA Act is unquestionably a potentially important development that we will continue to monitor closely. A downgrade of the sentiment factor in our country allocation framework is a likely outcome.

Subjects related to this article are:
Logo

Important legal information

The content displayed on this website is exclusively directed at qualified investors, as defined in the swiss collective investment schemes act of 23 june 2006 ("cisa") and its implementing ordinance, or at “independent asset managers” which meet additional requirements as set out below. Qualified investors are in particular regulated financial intermediaries such as banks, securities dealers, fund management companies and asset managers of collective investment schemes and central banks, regulated insurance companies, public entities and retirement benefits institutions with professional treasury or companies with professional treasury.

The contents, however, are not intended for non-qualified investors. By clicking "I agree" below, you confirm and acknowledge that you act in your capacity as qualified investor pursuant to CISA or as an “independent asset manager” who meets the additional requirements set out hereafter. In the event that you are an "independent asset manager" who meets all the requirements set out in Art. 3 para. 2 let. c) CISA in conjunction with Art. 3 CISO, by clicking "I Agree" below you confirm that you will use the content of this website only for those of your clients which are qualified investors pursuant to CISA.

Representative in Switzerland of the foreign funds registered with the Swiss Financial Market Supervisory Authority ("FINMA") for distribution in or from Switzerland to non-qualified investors is ACOLIN Fund Services AG, Affolternstrasse 56, 8050 Zürich, and the paying agent is UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zürich. Please consult www.finma.ch for a list of FINMA registered funds.

Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco/RobecoSAM AG product should only be made after reading the related legal documents such as management regulations, articles of association, prospectuses, key investor information documents and annual and semi-annual reports, which can be all be obtained free of charge at this website, at the registered seat of the representative in Switzerland, as well as at the Robeco/RobecoSAM AG offices in each country where Robeco has a presence. In respect of the funds distributed in Switzerland, the place of performance and jurisdiction is the registered office of the representative in Switzerland.

This website is not directed to any person in any jurisdiction where, by reason of that person's nationality, residence or otherwise, the publication or availability of this website is prohibited. Persons in respect of whom such prohibitions apply must not access this website.

I Disagree